These results aligned with the recent research by Faillie et al.17and the case report from Mathew et al.18which demonstrated a significantly elevated incidence risk of intestinal obstruction in patients using GLP‐1 RAs compared with those on SGLT‐2 inhibitors. The gene discussed is GLP1R; the disease is intestinal obstruction.